
Cue Biopharma CUE
$ 0.69
-1.24%
Quarterly report 2025-Q2
added 08-12-2025
Cue Biopharma P/E Ratio 2011-2025 | CUE
Annual P/E Ratio Cue Biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.26 | -1.7 | -2.04 | -8.01 | -8.67 | -9.17 | -2.59 | -13.4 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.26 | -13.4 | -5.86 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Graybug Vision
GRAY
|
-0.0575 | $ 0.44 | -11.23 % | $ 9.65 M | ||
|
AgeX Therapeutics
AGE
|
-0.00095 | $ 11.3 | -10.17 % | $ 12.2 K | - | |
|
Galera Therapeutics
GRTX
|
-0.403 | $ 0.14 | -32.59 % | $ 7.61 M | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-1.64 | $ 4.37 | -1.58 % | $ 28.1 M | ||
|
Axon Enterprise
AXON
|
106 | $ 584.64 | -2.97 % | $ 44.3 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-1.7 | $ 1.93 | -3.02 % | $ 22.1 M | ||
|
Cyclerion Therapeutics
CYCN
|
-2.14 | $ 1.8 | 10.97 % | $ 4.53 M | ||
|
Sorrento Therapeutics
SRNE
|
-1.38 | $ 0.27 | -29.58 % | $ 126 M | ||
|
ContraFect Corporation
CFRX
|
-0.0166 | $ 1.47 | -5.16 % | $ 5.39 M | ||
|
Orchard Therapeutics plc
ORTX
|
-4.46 | $ 4.93 | 1.02 % | $ 90.8 M | ||
|
Midatech Pharma plc
MTP
|
-14.5 | $ 0.29 | -18.52 % | $ 27.3 M | ||
|
Advaxis
ADXS
|
-0.0388 | $ 0.31 | -9.65 % | $ 45.9 M | ||
|
Heat Biologics, Inc.
HTBX
|
-1.26 | $ 3.93 | -5.76 % | $ 99.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
5.58 | $ 6.2 | - | $ 154 M | ||
|
Zymeworks
ZYME
|
-3.99 | $ 6.42 | - | $ 404 M | ||
|
Aeterna Zentaris
AEZS
|
-4.94 | $ 5.72 | 5.93 % | $ 314 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-0.859 | $ 10.5 | - | $ 231 M | ||
|
Kadmon Holdings, Inc.
KDMN
|
-7.46 | $ 9.5 | - | $ 1.7 B | ||
|
BioDelivery Sciences International
BDSI
|
3.63 | $ 2.58 | -4.8 % | $ 255 M | ||
|
Forte Biosciences
FBRX
|
-1.48 | $ 13.65 | 13.0 % | $ 87.3 M | ||
|
Zosano Pharma Corporation
ZSAN
|
-1.76 | $ 0.56 | 7.23 % | $ 2.72 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-0.203 | $ 0.5 | - | $ 7.46 M | ||
|
Kiromic BioPharma
KRBP
|
-0.18 | $ 3.15 | 6.61 % | $ 3.08 M | ||
|
Acceleron Pharma Inc.
XLRN
|
-55.2 | $ 179.68 | - | $ 10.9 B | ||
|
Genprex
GNPX
|
-0.132 | $ 4.17 | -0.95 % | $ 5.7 M | ||
|
Albireo Pharma
ALBO
|
-15.8 | $ 44.15 | -0.23 % | $ 916 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-8.57 | $ 0.32 | - | $ 23.9 M | ||
|
Trillium Therapeutics Inc.
TRIL
|
-18.6 | $ 18.44 | - | $ 1.94 B | ||
|
Kaleido Biosciences
KLDO
|
-0.816 | $ 0.29 | -3.69 % | $ 12.4 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
-1.56 | $ 2.19 | - | $ 105 M | ||
|
ImmuCell Corporation
ICCC
|
-19 | $ 6.16 | 0.98 % | $ 50.3 M | ||
|
IDEAYA Biosciences
IDYA
|
-6.19 | $ 30.82 | 1.9 % | $ 2.52 B | ||
|
Humanigen
HGEN
|
-0.177 | $ 0.04 | -81.12 % | $ 4.28 M | ||
|
Caladrius Biosciences
CLBS
|
-0.179 | $ 0.43 | -16.75 % | $ 25.8 M | ||
|
Aptinyx
APTX
|
-0.146 | $ 0.06 | -39.0 % | $ 4.57 M | ||
|
Tyme Technologies
TYME
|
-8.43 | $ 0.31 | 8.07 % | $ 54 M | ||
|
Forward Pharma A/S
FWP
|
-308 | $ 2.64 | -0.75 % | $ 18.7 M | ||
|
Jaguar Health
JAGX
|
-0.0364 | $ 1.67 | -6.46 % | $ 492 K | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | $ 0.39 | - | $ 26.5 M | ||
|
Celyad Oncology SA
CYAD
|
-1.57 | $ 0.47 | - | $ 12.5 M | ||
|
Brickell Biotech
BBI
|
-2 | $ 2.11 | -5.38 % | $ 6.06 M | ||
|
Genocea Biosciences
GNCA
|
-2.19 | $ 0.05 | -15.0 % | $ 3.04 M | ||
|
Codiak BioSciences
CDAK
|
-6.45 | $ 0.06 | -55.98 % | $ 2.15 M | ||
|
Concert Pharmaceuticals
CNCE
|
-1.29 | $ 8.37 | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
-1.33 | $ 3.17 | 1.93 % | $ 17.4 M | ||
|
Krystal Biotech
KRYS
|
56.3 | $ 199.71 | 0.9 % | $ 5.71 B | ||
|
Calithera Biosciences
CALA
|
-8.34 | $ 0.37 | -10.95 % | $ 876 K | ||
|
Kazia Therapeutics Limited
KZIA
|
-5.37 | $ 7.39 | 0.82 % | $ 979 M | ||
|
Forma Therapeutics Holdings
FMTX
|
-2.7 | $ 20.01 | - | $ 958 M | ||
|
Eli Lilly and Company
LLY
|
73.7 | $ 967.93 | 4.71 % | $ 872 B |